Company Information

CIN
Status
Date of Incorporation
02 January 2012
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2023
Last Annual Meeting
21 August 2023
Paid Up Capital
2,188,500,000
Authorised Capital
2,326,000,000

Directors

Chandra Reddy Tirumalareddy
Chandra Reddy Tirumalareddy
Director/Designated Partner
about 2 years ago
Venkateswararao Kondreddy
Venkateswararao Kondreddy
Director/Designated Partner
about 2 years ago
Mudiraj Saritha Rani
Mudiraj Saritha Rani
Director/Designated Partner
over 2 years ago
. Sapna
. Sapna
Director/Designated Partner
almost 3 years ago
Naga Venkata Kesavarapu
Naga Venkata Kesavarapu
Director/Designated Partner
almost 3 years ago
Satakarni Makkapati
Satakarni Makkapati
Director/Designated Partner
almost 3 years ago
Sivakumaran Meenakshisunderam
Sivakumaran Meenakshisunderam
Director/Designated Partner
over 7 years ago
Vinod Kumar Reddy Aerva
Vinod Kumar Reddy Aerva
Director/Designated Partner
over 9 years ago
Govindarajan Narayanan
Govindarajan Narayanan
Director
almost 14 years ago
Nityananda Reddy Kambam
Nityananda Reddy Kambam
Director
almost 14 years ago
Sarath Chandra Reddy Penaka
Sarath Chandra Reddy Penaka
Director
almost 14 years ago

Past Directors

. Singhal Shilpa
. Singhal Shilpa
Director
over 3 years ago

Patents

An Improved Process For Preparing Lh Rh Agonist

AN IMPROVED PROCESS FOR PREPARING LH-RH AGONIST The present invention provides an improved process for the preparation of LH-RH agonist by using a novel solid support linker of Formula II.

"An Improved Process For Preparing Lh Rh Agonists"

AN IMPROVED PROCESS FOR PREPARING LH-RH AGONISTS The present invention provides an improved process for the preparation of LH-RH agonists by using a novel solid support linker of Formula I. where R\ and R2 are CH3, C2H5, C3H7 and (CH2)n COOH with a proviso that any one of the Rj or R2 is (CH2)n COOH; wherein n is ...

An Improved Process For The Preparation Degarelix Acetate

A process for the preparation of Degarelix or a pharmaceutically acceptable salt thereof using combined solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS) by Fmoc strategy, proceeding via 9+] fragment protocol and also a process for the preparation of Degarelix or a pharmaceutically accep...

An Improved Process For The Preparation Of Degarelix Acetate

A process for the preparation of Degarelix or a pharmaceutically acceptable salt thereof; using liquid phase peptide synthesis (LPPS) by azide method proceeds via the coupling of suitable N-terminal peptide hydrazide with suitable C-terminal peptide.

A Process For The Preparation Of Pasireotide

ABSTARCT A PROCESS FOR THE PREPARATION OF PASIREOTIDE The present invention relates to a process for the preparation of Pasireotide of formula (I) and its acid addition salts. More particularly the present invention is directed to a process for the synthesis of Pasireotide of formula (I) having purity greater t...

An Improved Process For The Preparation Of Bivalirudin

The present invention relates to a process for the preparation of Bivalirudin which comprises: providing a protected dipeptide of formula (II), coupling of the protected dipeptide two times to a protected dodecapeptide on a solid support to produce a protected hexadecapeptide fragment of formula (IV); coupling of a ...

An Improved Process For The Preparation Of Etelcalcetide Hydrochloride

The present invention relates to process for the preparation of Elelcalcetide hydrochloride of Formula (I).

An Improved Process For The Preparation Of Plecanatide

The present invention relates to a process for the preparation of Plecanatide. which comprises preparation of three fragments such as Fragment A (7 amino acids). Fragment B (3 amino acids): Fragment C (6 amino acids) and coupling the fragments to provide Plecanatide followed by purification using buffer system com...

A Process For The Synthesis Of Tirzepatide

The present invention relates to a process for the preparation of Tirzepatide, which comprises preparation of three fragments such as Fragment A (1-12 amino acids), Fragment B (13-39 amino acids), Fragment C (29-39 amino acids); and coupling the fragments B with C to provide fragment D which is on further coupling w...

Documents

Form MGT-14-29122020-signed
Form SH-7-15122020-signed
Optional Attachment-(2)-14122020
Copy of the resolution for alteration of capital;-14122020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-14122020
Altered memorandum of assciation;-14122020
Altered memorandum of association-14122020
Optional Attachment-(1)-14122020
Form PAS-6-07112020_signed
Form MSME FORM I-29102020_signed
Form PAS-3-17102020_signed
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-16102020
Copy of Board or Shareholders? resolution-16102020
Form MGT-7-14102020_signed
List of share holders, debenture holders;-13102020
Copy of MGT-8-13102020
Form AOC-4(XBRL)-22092020_signed
Form PAS-6-11092020_signed
Form MGT-14-01092020_signed
Form DIR-12-01092020_signed
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-31082020
Optional Attachment-(1)-31082020
Form MR-1-15062020_signed
Copy of shareholders resolution-15062020
Copy of letter of consent to act  as  Managing Director/ Whole time Director/Manager ;             -15062020
Form PAS-3-01062020_signed
List of allottees. Attach separate list for each allotment (refer instruction kit for format).If not attached, then it shall be submitted separately in a CD.-01062020
Copy of Board or Shareholders? resolution-01062020
Form BEN - 2-19052020_signed
Declaration under section 90-19052020